Milestone Pharmaceuticals Inc. (MIST): Results of Operations and Financial Condition
Milestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST ® (etripamil) nasal spray Phase
How this was made
The 30-second read
Why it matters
Traders can update expectations for (1) commercial adoption and payer coverage, (2) clinical execution timing for ReVeRA-301, and (3) cash runway into H2 2027, which together shape risk/reward into upcoming regulatory and enrollment milestones.
Market read
The filing combines fresh commercial KPIs, a new clinical execution step (Phase 3 sites activated), and a cash runway update, which can drive near-term sentiment and positioning.
What to watch
Enrollment pace and regulatory pathway execution for the AFib-RVR sNDA are the key swing factors; commercial KPIs could plateau if payer coverage or prescriber adoption slows.
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
CARDAMYST launch indicators expanded materially and liquidity runway extends into the second half of 2027, but quarterly product revenue was $0.6 and net loss increased to $28.6 million as selling, general and administrative expense rose for the launch.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenues, three months ended June 30GAAP | $0.6 | – | – |
| Product revenues, six months ended June 30GAAP | $0.8 million | – | – |
| Research and development expense, three months ended June 30GAAP | $3.5 million | – | – |
| Research and development expense, six months ended June 30GAAP | $6.8 million | – | – |
| Selling, general and administrative expense, three months ended June 30GAAP | $22.6 million | – | – |
| Selling, general and administrative expense, six months ended June 30GAAP | $43.3 million | – | – |
| Net loss, three months ended June 30GAAP | $28.6 million | – | – |
| Net loss per share, three months ended June 30GAAP | $0.21 per share | – | – |
| Net loss, six months ended June 30GAAP | $54.7 million | – | – |
| Net loss per share, six months ended June 30GAAP | $0.41 per share | – | – |
| Cash, cash equivalents and short-term investmentsother | $170.6 million | – | – |
| Unique CARDAMYST prescribers through June 30other | More than 800 unique prescribers | – | – |
| Filled CARDAMYST scripts through June 30, 2026other | More than 1,500 scripts | – | – |
| PSVT patients with filled CARDAMYST scripts through June 30, 2026other | more than 1,300 patients with PSVT | – | – |
| Commercial lives covered through Q2other | approximately 25% | – | – |
| Commercial lives covered to dateother | approximately 50% | – | – |
into the second half of 2027 outlook
- NoteThe Company currently expects its cash, cash equivalents and short-term investments to be sufficient to cover operating expenses and capital expenditure into the second half of 2027.
- NoteRegulatory review of the marketing authorization application for etripamil for PSVT in Europe remains on track for a decision from the European Medicines Agency (EMA) in the first half of 2027.
- NotePreviously announced plans to enroll the first patient in the second half of 2026 remain on track.
What drove it
- More than 800 unique prescribers have started patients on CARDAMYST through June 30, compared to approximately 200 at the end of Q1.
- More than 1,500 scripts for CARDAMYST have been filled for more than 1,300 patients with PSVT through June 30, 2026, compared to approximately 300 scripts for 300 patients at the end of Q1.
- Covered lives have significantly grown to approximately 50% to date as a result of recently reported formulary coverage for CARDAMYST from UnitedHealthcare and several other prominent commercial insurers.
- Research and development expense decreased as a result of a decrease in outside service costs related to drug development and research.
- The ReVeRA-301 Phase 3 registrational trial evaluating self-administered etripamil as a potential treatment for patients with AFib-RVR is now open, with several sites activated and evaluating patients for enrollment.
Concerns
- Product revenues were $0.6 during the three months ended June 30, 2026.
- Selling, general and administrative expense for the three months ended June 30, 2026, was $22.6 million, compared with $8.9 million for the prior year period.
- Net loss for the three months ended June 30, 2026, was $28.6 million, compared to a net loss of $13.0 million for the prior year period.
- Commercial lives covered remained relatively unchanged through Q2 at approximately 25%.
What to watch
- CARDAMYST prescription growth from a widening base of new prescribers.
- The effect of recently reported formulary coverage from UnitedHealthcare and several other prominent commercial insurers on covered lives and prescriptions.
- Enrollment of the first patient in the ReVeRA-301 Phase 3 registrational trial in the second half of 2026.
- A decision from the European Medicines Agency on the etripamil marketing authorization application for PSVT in the first half of 2027.
- The Company’s stated cash runway into the second half of 2027.
Balance sheet and cash flow
- As of June 30, 2026, Milestone had cash, cash equivalents, and short-term investments of $170.6 million, compared to $106.0 million as of December 31, 2025.
- The Company currently expects its cash, cash equivalents and short-term investments to be sufficient to cover operating expenses and capital expenditure into the second half of 2027.
Analysis
Milestone reported its first quarterly CARDAMYST product revenue following the mid-February 2026 launch, with product revenues of $0.6 during the three months ended June 30, 2026, versus no product revenue in the prior-year period. Launch activity expanded from the end of Q1, with more than 800 unique prescribers, more than 1,500 filled scripts, and more than 1,300 patients through June 30. The company identified prescription growth from a widening base of new prescribers as a central launch driver.
Access is a key element of the commercial read. Commercial lives covered remained relatively unchanged through Q2 at approximately 25%, while coverage had grown to approximately 50% to date following formulary coverage from UnitedHealthcare and several other prominent commercial insurers. The distinction between coverage through Q2 and coverage to date is important, as the recent access gains had not yet been reflected in the reported quarterly coverage level.
Expenses reflect the commercial launch. Quarterly selling, general and administrative expense was $22.6 million compared with $8.9 million in the prior-year period, with the increase attributed to personnel, professional, and other operational expenses related to CARDAMYST. Research and development expense was $3.5 million compared with $3.7 million, driven lower by outside service costs related to drug development and research. Net loss was $28.6 million, or $0.21 per share, compared with a net loss of $13.0 million, or $0.20 per share.
Capital resources increased to $170.6 million in cash, cash equivalents and short-term investments as of June 30, 2026, compared with $106.0 million as of December 31, 2025. Management expects these resources to cover operating expenses and capital expenditure into the second half of 2027. Clinically, ReVeRA-301 in AFib-RVR is open with several sites activated, and the company said its plan to enroll the first patient in the second half of 2026 remains on track. The European PSVT application remains on track for an EMA decision in the first half of 2027.
The quarter therefore combines clear early commercial activity and recent coverage expansion with a still-small reported product revenue base and substantially higher launch-related selling, general and administrative expense. Near-term attention centers on whether the broader formulary coverage translates into continued prescription growth, progress in ReVeRA-301 enrollment, the EMA timing, and execution against the stated cash runway.
Management, verbatim
We continue to make steady progress on the launch of CARDAMYST for PSVT supported by prescription growth from a widening base of new prescribers and a meaningful recent increase in insurance coverage. We are confident that this increased coverage paired with optimized sales and marketing strategies positions us to drive acceleration of CARDAMYST prescriptions moving forward,
Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals
Separately, we have activated several sites in our Phase 3 ReVeRA-301 trial in AFib-RVR and look forward to enrolling the first patient. AFib-RVR is one of the most common heart arrhythmias, affecting millions of Americans. The trial is evaluating the same self-administered regimen already approved in PSVT, giving us a clear path toward extending etripamil to a larger, adjacent patient population.
Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals
Not in the filing
stated, not guessed- Total revenue
- Revenue by reportable segment
- Gross profit and gross margin
- Operating income or loss
- Income tax expense or benefit and tax rate
- Non-GAAP revenue, earnings, operating income, net income, or EPS
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt
- Share repurchases
- Dividends
- Quantitative revenue guidance
- Quantitative gross-margin guidance
- Quantitative operating-expense guidance
- Quantitative tax-rate guidance
- Prior-quarter financial comparisons for product revenue, research and development expense, selling, general and administrative expense, net loss, and net loss per share
- Percentage year-over-year and quarter-over-quarter changes for reported financial metrics
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K with Q2 2026 results and corporate updates for Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray and its Phase 3 AFib-RVR program.
Ticker impact
Milestone reports CARDAMYST launch traction, formulary coverage growth to ~50% of lives, and activates Phase 3 ReVeRA-301 AFib-RVR sites.
Likely positive bias for the next session and into the investor call, with follow-through dependent on whether coverage and enrollment momentum persists.
The filing adds concrete commercial KPIs (prescribers, scripts, coverage) and a fresh clinical milestone (Phase 3 sites activated, first patient expected H2 2026), alongside a cash runway update into H2 2027.
Market effects
Adds a datapoint on commercialization momentum for intranasal etripamil in cardiovascular arrhythmias, which can influence sentiment toward small-cap specialty pharma execution.
Limited direct regional read-through beyond US commercial payer coverage and US-listed biotech risk appetite.
EMA decision timing for PSVT in Europe (H1 2027) and NMPA review in China keep the program on a global regulatory watchlist.
Counterpoint
Coverage is improving, but product revenue remains small and SG&A has surged, so near-term fundamentals may not yet justify a sustained rerating.
Key entities
- companyMilestone Pharmaceuticals Inc.
Nasdaq-listed biopharmaceutical company developing and commercializing etripamil nasal spray for arrhythmias.
- productCARDAMYST (etripamil) nasal spray
Commercial product launched for PSVT in mid-February 2026, with expanding payer coverage and prescription growth.
- clinical_trialReVeRA-301
Phase 3 registrational trial evaluating self-administered etripamil for AFib-RVR; sites activated and first patient enrollment expected in H2 2026.
- regulatorEuropean Medicines Agency (EMA)
Reviewing the PSVT marketing authorization application, with decision expected in H1 2027.
- regulatorChina National Medical Products Administration (NMPA)
Reviewing the PSVT NDA in China; partner Everest Medicines handles engagement.
